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Adult T-cell leukemia/lymphoma (ATLL) is a rare and
highly aggressive type of peripheral T-cell lymphoma
associated with human T-lymphotropic virus, type I
(HTLV-I) infection. ATLL has a long latency and only a
small percentage of HTLV-I infected individuals develop
ATLL, suggesting the requirement of additional genetic
events for neoplastic transformation of HTLV-I infected
lymphocytes. The disease is endemic in several regions of
the world, in particular, southwestern Japan and the
Caribbean basin. The clinical features of Caribbean ATLL
have been reported to differ from Japanese cases, includ-
ing a younger age at diagnosis, higher frequency of the
lymphomatous subtype, and a more aggressive clinical
course [1–7]. A number of publications have described
the cytogenetic profile of Japanese ATLL [8–11]; however,
cytogenetic data on Caribbean ATLL are limited [5,6]. In
this study, we assessed the cytogenetic alterations in a
large series of Caribbean ATLL cases to investigate
whether the differences in the types and frequencies of
karyotype abnormalities account for the reported differ-
ences in clinical presentation and outcome between
Japanese and Caribbean patients.
A total of 41 Caribbean ATLL patients diagnosed at
our institution from 2003 to 2018 were evaluated. Clinical
data, morphologic, immunophenotypic, and cytogenetic
findings were reviewed. G-band karyotyping was per-
formed after overnight and 72 hr Phytohaemagglutinin-
stimulated cultures and karyotypes described according
to the International System for Human Cytogenomic
Nomenclature (ISCN). Karyotype abnormalities were cate-
gorized as simple (<3 aberrations) or complex (3 aber-
rations). Each gain, loss or breakpoint is regarded as one
aberration. Complex karyotypes were further sub-catego-
rized as low complex (3–10 aberrations) and high com-
plex (>10 aberrations). A total of 90 ATLL samples were
analyzed (37 peripheral blood, 40 bone marrow, 7 lymph
node, 1 subcutaneous mass, 1 mesenteric mass, 2 lung
tissue, 1 skin biopsy, and 1 bronchial fluid) from the 41
Caribbean patients (26 F/15 M, age 16–73 years, median
52). The cases included 26 acute, 12 lymphomatous and
3 smoldering variants of ATLL. Abnormal karyotypes were
detected in 45 samples from 31 patients. Thirty-four sam-
ples, including all 3 smoldering ATLL cases, demonstrated
normal karyotypes and karyotyping failed in 11 samples.
The tumors of 31 patients with abnormal karyotypes (in
at least one sample) comprised acute (n¼ 22) and lym-
phomatous (n¼ 9) variants of ATLL were included in this
analysis. Most patients received multiple chemotherapies,
two patients also received stem cell transplant
(Supplemental Table 1). The overall survival (OS-defined
as the duration from initial diagnosis to the date of
death, or the last follow-up) of these patients ranged
from 10 days to 43 months (median 8 months) after ini-
tial diagnosis. The clinical data, cytogenetic findings,
overall survival, and treatment information are summar-
ized in Supplemental Table 1. Two-sided Mann-Whitney
U Test was used to compare the differences in overall
survival and prognostic indices in each cytogenetic group
(with and without particular cytogenetic abnormality).
All 31 patients exhibited complex karyotypes in at
least one sample from each case. Low complex karyo-
types were seen in 12 (38.7%) and high complex karyo-
types in 19 (61.3%) cases. Near-diploid karyotype was
seen in the majority of the patients (n¼ 24, 77.4%) and
near-tetraploid karyotypes in 7 patients (22.6%).
Karyotype heterogeneity (presence of subclones, defined
as related clones with additional abnormalities compared
to the stemline) was observed in 20 patients (64.5%).
Copy number losses most frequently involved chromo-
somes 14 (9 cases, 29.0%), followed by 13 and 19
(7 each, 22.6%), and 5 and 17 (6 each, 19.4%). No consist-
ent gain of chromosomes was seen. Among deletions, 6q
(9, 29.0%) and 3q (7, 22.6%) were most frequent.
Recurrent rearrangement breakpoints were seen in more
than 10% of patients at 1q21 (6, 19%), 3p21 (6, 19%),
6q21 (8, 26%), 9p13 (4, 13%), 14p11.2 (5, 16%), 14q32
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(5, 16%), 17p11.2 (4, 13%), 19p13 (4, 13%), and 19q13.3
(4, 13%) (Table 1). Additionally, homogenously staining
regions, changes suggestive of gene amplification, were
identified in two patients.
To assess any impact of cytogenetic abnormalities on
clinical outcomes, we compared particular type or pat-
tern of chromosomal changes with OS. We found high
complex karyotype (>10 abnormalities) was strongly
associated with shorter survival (Table 1, p¼ .013). The
incidence of high complex karyotypes was more frequent
(12/16 cases; 75%) in patients with OS 8 months com-
pared to >8 months OS (5/13 cases; 42.5%). Furthermore,
the OS was 12 months in cases exhibited low complex
karyotypes compared to 6.5 months in patients with high
complex karyotypes (Table 1). These differences were
statistically significant (p< .05) suggesting chromosome
complexity predicts shorter survival. Cases with loss of
chromosome 13 or deletion 13q (n¼ 9, 29%) exhibited
significantly shorter OS (3 months), compared to cases
with retained chromosome 13q (OS ¼ 9.5 months,
p¼ .04). Aberrations of 17p (TP53 deletion by FISH, loss
of 17, 17p deletion, or 17p rearrangement by karyotype)
were detected in a significant number of cases (n¼ 11,
35.4%), and showed a worse outcome (median OS ¼ 6.5
months for 17p abnormalities versus 10.5 months for
cases without 17p abnormalities), although not statistic-
ally significant. Cases with p16 (CDKN2A) deletion (n¼ 2)
and HSR’s (n¼ 2) had short OS (10 days and 2 months,
and 15 and 3 months, respectively). Discordant karyo-
types were seen in two samples from one patient (#15)
obtained 4 years apart, with the later specimen exhibit-
ing a complex karyotype with TP53 deletion. One case
(#10) showed karyotype progression within a few
months, with acquisition of HSR. Both these events were
associated with very short survival. These findings further
suggest that deletions of 17p (TP53) and 9p (CDKN2A), as
well gene amplifications may serve as poor prognostic
markers in ATLL. Aberrations of ploidy, clonal heterogen-
eity, treatment-naïve versus treated cases, acute versus
lymphomatous subtypes did not show statistically signifi-
cant differences in overall survival. In addition, we com-
pared the observed cytogenetic abnormalities with two
known prognostic indices in ATLL: serum calcium and
lactate dehydrogenase (LDH) levels. We found patients
with loss of chromosome 13 or deletion 13q had signifi-
cantly higher LDH levels (mean ¼ 2571mg/dL) compared
to patients without (mean ¼ 1058mg/dL, p< .05). No
cytogenetic aberration was found to be significantly
correlated with calcium levels.
To the best of our knowledge, this is the largest series
of cytogenetic analysis of the Caribbean ATLL patients in
the United States. The presence of high complex chromo-
somal aberrations was a frequent feature of our
Caribbean ATLL cohort and included numerical abnormal-
ities as well as structural chromosomal rearrangements.
In a recent study of Caribbean ATLL patients [5], which
included 13 patients with abnormal cytogenetics (12
acute and 1 lymphomatous variants), the authors found
the most commonly affected chromosome was 14 (8/13,
61.5%), followed by chromosomes 1, 9, 11, and 20 (46.2%
each). Recurrent deletions noted were deletions of 3q21,
5q33, and 20q11.2. Some of these findings are similar to
our cohort, such as chromosome 14 being the most com-
monly affected chromosome and high percentage of
recurrent deletion involving 3q21. However, many of
their findings are different from our study, probably due
to low number of cases and higher percentage of acute
variant of ATLL included in their cohort. No clinical corre-
lations were reported in the study.
Although several of the cytogenetic features in our
cohort were similar to Japanese ATLL, certain significant
variations in frequency of specific chromosomal abnor-
malities were observed. In the largest Japanese study [8],
the most frequent numerical changes in chromosomes
were trisomy 3 (21%), 7 (10%), and 21 (9%), monosomy X
(38% in females), and Y (17% in males), while our cohort
showed high frequency of copy number loss in chromo-
some 14 (29.0%), followed by 13 and 19 (22.6% each),
and 5 and 17 (19.4% each). The most common recurrent
chromosomal rearrangement breakpoints in the Japanese
study was 14q32 (28%), followed by 14q11 (14%), while
in our cohort were 6q21 (25.8%), 1q21 (19.4%), 3p21
(19.4%), and 14q32 (16.1%). Similar to the Japanese stud-
ies [9,11], deletions most frequently involved 6q in our
cohort (29.0%). Our cohort also showed much higher fre-
quency of cases with high complex karyotype (>10 aber-
rations, 61.3%) which was associated with significant
Table 1. Major karyotype abnormalities and their correlations
with survival in 31 Caribbean ATLL patients.






Low complex (3–10 aberrations) 12 (38.7) 12
High complex (>10 aberrations) 19 (61.3) 6.5 .013
Hetrogeneity (with subclones) 20 (64.5) 8 .245
Near diploid 24 (77.4) 8
Near tetraploid 7 (22.6) 8 .811
Chromosome 14 loss 9 (29.0) 7 .363
Chromosome 13 loss 7 (22.6) 3 .043
Chromosome 19 loss 7 (22.6)
Chromosome 17 loss 6 (19.4)
Chromosome 5 loss 6 (19.4)
Del (6q) 9 (29.0) 7 .384
Del (3q) 7 (22.6)
Del (17p) (including 17 loss) 11 (35.4) 6.5 .303











All p values were calculated in comparison to cases without the
corresponding cytogenetic abnormalities.p value was calculated including two additional cases of del 13q.
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shorter survival. Similarly, in the Japanese study [9], mul-
tiple chromosomal breaks (6, 42%) were found to cor-
relate with shorter overall survival. In addition, they
found abnormalities of many chromosomes (e.g. 1p,
1p22, 1q, 1q10-21, 2q, 3q, 3q10-12, 3q21, 14q, and
14q32) correlated with shorter survival, which we did not
find in our cohort. Instead, we found loss of chromosome
13 or del13q to be associated with statistically significant
shorter survival. Aberrations of 17p were seen in a large
proportion of our cases (35.5%) and associated with
shorter survival, which is in accord with published data
from Japanese ATLL [9,10].
Some factors might have contributed to the observed
cytogenetic differences between Caribbean and Japanese
ATLL patients. For example, our cohort included only
aggressive clinical variants (lymphomatous and acute),
while Japanese studies included also indolent variants
(chronic and smoldering); Many of our patients had
relapsed/refractory disease (12/31, 38.7%) when initially
presented to our hospital, compared to newly diagnosed
ATLL patients in the Japanese cohorts. Despite these con-
founding factors, the Caribbean ATLL is likely biologically
distinct from the Japanese ATLL. Indeed, a most recent
study reported targeted exon sequencing in 30 North
American ATLL patients and compared the results to the
Japanese ATLL cases [12]. The authors found a higher
percentage of mutations in epigenetic and histone modi-
fying genes and lower frequency of mutations in JAK/
STAT and TCR/NF-jB pathway genes in their North
American ATLL cohort as compared to the Japanese
ATLL. This is the first molecular genetic data on
Caribbean ATLL patients and further supports the distinc-
tion between Caribbean and Japanese ATLL at the
molecular level. Further studies with more Caribbean
ATLL cases included are needed to consolidate these
findings and to determine the role of host and/or envir-
onmental socioeconomic factors, or differences in clinical
care and therapy.
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